Dr. Grey AI

Sincalide (Kinevac)

Peptide

Sincalide is the synthetic C-terminal octapeptide of cholecystokinin (CCK-8). FDA-approved in 1976 for diagnostic imaging. Stimulates gallbladder contraction for ejection fraction measurement. GBEF <38% (60-min infusion) indicates dysfunction. 81% symptom relief post-cholecystectomy in dyskinesia patients. Also used for pancreatic function testing with secretin.

Quick Answer

What it is

Sincalide is the synthetic C-terminal octapeptide of cholecystokinin (CCK-8). FDA-approved in 1976 for diagnostic imaging.

Key findings

  • Grade A: Gallbladder Ejection Fraction (Biliary Dyskinesia)
  • Grade A: Gallbladder Contraction (Biliary Dyskinesia)
  • Grade A: Pancreatic Enzyme Secretion (Pancreatitis)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Sincalide (Kinevac)

Quick Facts: Sincalide (Kinevac)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:9
  • Grade A Findings:3
  • Grade B Findings:2
  • Key Effect:Biliary Dyskinesia
A3
B2
C3
D1
2 conditions · 9 outcomes

Detailed Outcomes

|
A
Gallbladder Ejection Fraction
Standard 60-min sincalide infusion establishes GBEF normal values. Lower limit of normal: 38% at 1% CI. GBEF <35-40% indicates gallbladder dysfunction. Coefficient of variation 19% for 60-min protocol.
large↑Improves
A
Gallbladder Contraction
Reduces gallbladder radiographic size by ≥40% in normal patients. Enables visualization of gallbladder function via cholescintigraphy. Gold standard for acalculous cholecystitis diagnosis.
large↑Improves
B
Surgical Outcome Prediction
81.4% complete symptom resolution after cholecystectomy in low GBEF patients. Systematic review of 1,710 patients. GBEF alone may not reliably predict outcomes; other factors contribute.
moderate↑Improves
A
Pancreatic Enzyme Secretion
Combined with secretin for pancreatic function testing. Stimulates enzyme (lipase, amylase) secretion into duodenum. Used for duodenal aspirate analysis in chronic pancreatitis evaluation.
large↑Improves
B
Liver Protection
7 human trials support this finding. Human clinical trial data available.
small↑Improves
C
GI Protection
4 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Pain
3 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
C
Anti-Cancer Activity
3 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Blood Glucose Control
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves

Research Citations (29)

Gastrointestinal cholecystokinin signaling pathway drugs modulate osteogenic/cementogenic differentiation of human periodontal ligament stem cells.
(2025)
PMID: 40032153
Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion.
(2024)
PMID: 37993991
HDAC1-Mediated Downregulation of NEU1 Exacerbates the Aggressiveness of Cervical Cancer.
(2024)
PMID: 38505872
Defining Biliary Hyperkinesia and the Role of Cholecystectomy
(2023)
PMID: 37366537
C1QTNF6 Targeted by MiR-184 Regulates the Proliferation, Migration, and Invasion of Lung Adenocarcinoma Cells.
(2022)
PMID: 35578071
Cholescintigraphy may have a role in selecting patients with biliary dyskinesia for cholecystectomy: a systematic review
(2020)
PMID: 32479706
Utilizing the Cholecystagogue, Ensure Plus, Results in Similar Hepatobiliary Scintigraphy Study Results and Patient Outcomes Status Post Cholecystectomy, in Comparison With Sincalide.
(2020)
PMID: 31789906
Sincalide: A Review of Clinical Utility, Proper Infusion Methodology, and Alternative Cholecystogogues.
(2019)
PMID: 31019045
Endoscopic Pancreatic Function Test using Combined Secretin and Cholecystokinin Stimulation for the Evaluation of Chronic Pancreatitis
(2015)
PMID: 25773097
Pain provocation and low gallbladder ejection fraction with CCK cholescintigraphy are not predictive of chronic acalculous gallbladder disease symptom relief after cholecystectomy
(2014)
PMID: 24852884

Related Peptides

Secretin (ChiRhoStim)

Peptide

1 shared condition · 12 outcomes

Secretin is a 27-amino acid peptide hormone. FDA-approved in 2004 for diagnostic use. Stimulates pancreatic bicarbonate secretion for exocrine function testing. Secretin stimulation test has 92-96% sensitivity for gastrinoma/ZES diagnosis. Used in secretin-enhanced MRCP with 89% sensitivity for chronic pancreatitis detection. Also facilitates ERCP cannulation.